Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

NCT02315196 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Estrogen Receptor-negative Breast Cancer
HER2-negative Breast Cancer
Progesterone Receptor-negative Breast Cancer
Stage IIA Breast Cancer
Stage IIB Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Triple-negative Breast Cancer

Interventions

DRUG: pegylated liposomal doxorubicin hydrochloride
DRUG: epirubicin hydrochloride
DRUG: carboplatin
PROCEDURE: therapeutic conventional surgery
DRUG: paclitaxel
OTHER: laboratory biomarker analysis
OTHER: quality-of-life assessment

Sponsor

Rutgers, The State University of New Jersey

Collaborators

[object Object]
[object Object]